Metastatic melanoma remains an incurable disease for many patients due to the limited
success of targeted and immunotherapies. BRAF and MEK inhibitors reduce metastatic …

One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and
MEK inhibition progress within 6 months. Treatment options for these patients remain …

Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF
and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and …

Background The sustained clinical activity of the BRAF inhibitor vemurafenib
(PLX4032/RG7204) in patients with BRAFV600 mutant melanoma is limited primarily by the …

Combined BRAF and MEK inhibition is a standard of care in patients with advanced BRAF-
mutant melanoma, but acquired resistance remains a challenge that limits response …

The mitogen-activated protein kinase (MAPK) pathway has emerged as a central target for
melanoma therapy due to its persistent activation in the majority of tumors. Several BRAF …

The identification of driver mutations in melanoma has changed the field of cancer treatment.
BRAF and NRAS mutations are predominant in melanoma and lead to overactivation of the …

Patients with advanced melanoma have traditionally had very poor prognosis. However,
since 2011 better understanding of the biology and epidemiology of this disease has …

Most melanomas harbor oncogenic BRAFV600 mutations, which constitutively activate the
MAPK pathway. Although MAPK pathway inhibitors show clinical benefit in BRAFV600 …

Abstract Treatment of BRAF-mutant melanoma with combined dabrafenib and trametinib,
which target RAF and the downstream MAP–ERK kinase (MEK) 1 and MEK2 kinases …